Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

C. diff colitis is inflammation of a person’s colon due to contagious bacteria. Most people with C. diff colitis fully recover, but in rare cases the condition can be life threatening. It is possible ...

A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

Five insights from the report, written by Clayton Dalton, MD, a resident physician at Boston-based Massachusetts General Hospital: 1. In addition to antibiotic use being a risk factor for C. diff, ...

FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...

Some people will get repeat infections from Clostridium difficile (C. diff). They may develop the same symptoms they had before such as diarrhea, stomach pain, and loss of appetite. However, the only ...

The Food and Drug Administration has approved a fecal microbiota pill to treat recurrent infections caused by Clostridium difficile (C. diff), an antibiotic-resistant bacterium deemed an urgent threat ...

Please provide your email address to receive an email when new articles are posted on . Exposure to a contaminated nearly doubles a patient’s risk for hospital-onset C. difficile infection. This ...

Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections. Clinical trials showed Vowst significantly ...

Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote despite some skepticism from a handful of members, setting up the asset for potential approval to treat Clostridioides difficile ...